Market
Foundayo’s Slow Start And Amazon Entry Test Eli Lilly Valuation
YahooApr 25, 2026
Eli Lilly’s new oral obesity pill, Foundayo, is seeing slower initial prescription uptake than early expectations in its first weeks on the market. Recent data suggests Foundayo’s launch trails the early momentum seen in Novo Nordisk’s oral Wegovy pill. Amazon has entered the GLP-1 obesity and diabetes treatment space with a clinical and pharmacy program, adding fresh competition. Eli Lilly (NYSE:LLY) is coming into this news after a sharp multiyear share price run, with the stock up about...
